Global Medical Directory is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

miotepa 100
Connect with this vendor - Learn about this product

MIOTEPA 100 - Thiotepa for Injection USP 100 mg


Medicine composition: Thiotepa for Injection USP 100 mg

Dosage Form: Injection

Packing: 1*Vial

Market Authorization: MBA Pharmaceuticals Pvt Ltd

Country Of Origin: India

Similar to Tepadine


Thiotepa is indicated to reduce the risk of graft rejection when used in conjunction with high-dose Busulfan and cyclophosphamide as a preparative regimen for allogeneic hematopoietic progenitor (stem) cell transplantation (Hscn for pediatric patients with class3 beta-thalassemia.

Thiotepa is indicated for the treatment of adenocarcinoma of the breast or ovary.

Thiotepa is indicated for controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities.

Thiotepa is indicated for the treatment of superficial papillary carcinoma of the urinary bladder.